These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations.
    Author: Poirier JM, Berlioz F, Isnard F, Cheymol G.
    Journal: Therapie; 1996; 51(2):163-7. PubMed ID: 8763051.
    Abstract:
    Itraconazole is a new oral triazole antifungal agent that is effective against a wide range of fungal pathogens, including Aspergillus species. There has been a considerable increase in recent years in its use in prophylaxis of aspergillosis in neutropenic patients. A total of 74 trough concentrations of itraconazole+active metabolite were retrospectively analysed at steady state in 16 patients admitted to hospital for acute myeloid leukaemia (12) or malignant lymphoma (4). The minimum therapeutic concentration (itraconazole+hydroxyitraconazole = 1000 ng/ml) was never reached in 31 per cent of patients (5/16) and a constant efficient plasma concentration was obtained in only 19 per cent (3/16) with a daily regimen of 400-600 mg. The plasma levels of patients at the same daily dose differed up to 15-fold. This study confirms the pronounced inter-patient variability of unchanged itraconazole concentrations previously found in volunteers and patients. The plasma levels in six patients during successive chemotherapy treatments also varied greatly. Intra-individual differences were more accurately examined in six patients given 600 mg itraconazole/day during their first chemotherapy treatment. The trough plasma concentrations on day 15 and day 25 varied from -53 to +245 per cent. These results indicate that the plasma itraconazole concentration of neutropenic patients must be monitored to ensure that each individual is given a clinically effective dose.
    [Abstract] [Full Text] [Related] [New Search]